Medtech Acquisition Corp. (TLSIW)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
TLSIW Chart
Medtech Acquisition Corp. (TLSIW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Medtech Acquisition Corp. ever had a stock split?
Medtech Acquisition Corp. Profile
| - Industry | - Sector | Ms. Mary T. Szela B.S.N., M.B.A. CEO | NASDAQ (NMS) Exchange | 89680M101 CUSIP |
| US Country | 102 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
TriSalus Life Sciences, Inc. stands at the forefront of medical technology innovation, centering its research and development efforts on advanced drug delivery technologies and immunotherapy treatments specifically targeting liver and pancreatic cancers. Established in 2009 and based in Westminster, Colorado, the company is dedicated to addressing the complex treatment needs of patients suffering from these devastating diseases. TriSalus aims to revolutionize the approach to cancer treatment by enhancing drug delivery systems and developing novel immunotherapeutics that could potentially improve outcomes for patients battling with liver and pancreatic cancers, as well as their metastases.
Products and Services
- Pressure Enabled Drug Delivery (PEDD) Infusion Systems
- Pancreatic Retrograde Venous Infusion Device
- Nelitolimod (Investigational Immunotherapeutic)
TriSalus has developed an innovative suite of PEDD infusion systems, including the TriNav infusion system. This technology is specifically designed to enhance the effectiveness of transarterial radioembolization (TARE) and chemoembolization procedures. It aims to address the treatment of patients who suffer from liver cancer and its metastases by optimizing the delivery of therapeutic agents directly to the cancerous tissues. This innovative approach helps to maximize treatment efficacy while potentially reducing systemic side effects.
Currently in Phase 1 clinical trial, this device represents a significant leap forward in the treatment of locally advanced pancreatic cancer. It exemplifies TriSalus's commitment to pioneering drug delivery methodologies that can directly target the pancreatic tumor environment. By facilitating a more effective delivery of chemotherapeutic agents or other therapeutic substances, this device aims to improve the treatment outcomes for patients facing this challenging diagnosis.
Nelitolimod is a groundbreaking investigational immunotherapeutic currently undergoing Phase 1 clinical trials. It is being studied for its potential to treat a variety of cancers, including uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. Nelitolimod embodies the company's innovative spirit by potentially harnessing the body's immune system to fight cancer more effectively, showcasing TriSalus's expertise in the realm of immune-oncology therapeutics.
